The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| MDWD | +7.75% | -26.26% | -5.91% | -85% |
| S&P | +14.49% | +91.09% | +13.83% | +266% |
MediWound Ltd. is a biopharmaceutical company, which engages in the development, manufacture, and commercialization of products to address needs in the fields of severe burns, chronic wounds, and other hard-to-heal wounds. Its product is NexoBrid. The company was founded by Lior Rosenberg and Marian Gorecki in January 2000 and is headquartered in Yavne, Israel.
Pfizer, AstraZeneca, MediWound, and Gilead Sciences could all make waves in health care news this Wednesday morning.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $5.71M | 12.7% |
| Gross Profit | $1.34M | 200.2% |
| Gross Margin | 23.51% | 14.7% |
| Market Cap | $209.35M | 45.3% |
| Market Cap / Employee | $1.89M | 0.0% |
| Employees | 111 | 11.0% |
| Net Income | -$13.32M | -111.2% |
| EBITDA | -$5.32M | -29.0% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $1.06M | -72.1% |
| Accounts Receivable | $5.01M | 71.5% |
| Inventory | 3.8 | 19.7% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $8.07M | 27.0% |
| Short Term Debt | $0.82M | -45.1% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -45.43% | -12.6% |
| Return On Invested Capital | 11.43% | -18.5% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$6.92M | -14.0% |
| Operating Free Cash Flow | -$5.80M | -88.6% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 9.39 | 5.61 | 5.38 | 6.97 | 9.76% |
| Price to Sales | 9.63 | 9.50 | 8.72 | 10.57 | 47.81% |
| Price to Tangible Book Value | 9.46 | 5.63 | 5.39 | 6.99 | 9.34% |
| Enterprise Value to EBITDA | -32.09 | -27.41 | -28.06 | -35.01 | 17.81% |
| Return on Equity | -83.4% | -96.3% | -77.9% | -148.6% | 96.47% |
| Total Debt | $7.19M | $6.93M | $7.11M | $8.89M | 13.26% |
No podcast episodes available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
